Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubicin in Recurrent Glioblastoma Multiforme
NCT04915404Phase 2Terminated
- Sponsor
- WPD Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of berubicin in glioblastoma multiforme (GBM), sponsored by WPD Pharmaceuticals. Started Dec 2022; status: terminated.
02
Drugs
berubicin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04915404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915404.